The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation - PubMed (original) (raw)
. 2005 Dec 6;44(48):15842-57.
doi: 10.1021/bi0515220.
Affiliations
- PMID: 16313187
- DOI: 10.1021/bi0515220
The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation
Kian Kani et al. Biochemistry. 2005.
Abstract
The extracellular, ligand binding regions of ErbB receptors consist of four domains that can assume at least two alternative conformations, extended and locked. The locked conformation, observed in several crystal structures, is held together by a noncovalent intramolecular tether and is incompatible with current models for receptor dimerization and ligand activation. Based on structures of ligand-receptor complexes in the extended conformation, the high affinity ligand binding pocket between domains I and III is disrupted in the locked conformation. Therefore the biological role of the locked conformation is not clear. To address the impact of the locked conformation on ligand binding, we compared extracellular domains of wild-type ErbB3, mutant domains in a constitutively locked or extended conformation and partial extracellular domain constructs. We found that the constitutively locked receptor domains and truncated constructs carrying only domains I-II or III-IV strongly bind ligand, albeit with reduced affinity compared to wild-type receptor. This suggests that the locked conformation cannot be discounted for ligand binding. The significant binding by both partial interfaces in domains I and III also suggests that "partial bivalency" may be the reason for the low nanomolar and high picomolar binding observed for ErbB3 in the respective "low" and high affinity states. In contrast to EGFR (ErbB1), ErbB3 retains high ligand binding affinity at an endosome-comparable pH in both the extended and locked conformations. Ligand affinity for the locked conformation even improves at low pH. For ErbB3, the contribution of domain I to ligand binding is strong and increases at low pH while its contribution is thought to be minimal for EGFR, regardless of pH. This shift in domain contribution and pH dependency provides a mechanistic explanation for some of the divergent properties of EGFR and ErbB3.
Similar articles
- Structure of the extracellular region of HER3 reveals an interdomain tether.
Cho HS, Leahy DJ. Cho HS, et al. Science. 2002 Aug 23;297(5585):1330-3. doi: 10.1126/science.1074611. Epub 2002 Aug 1. Science. 2002. PMID: 12154198 - Epidermal growth factor mutant with wild-type affinity for both ErbB1 and ErbB3.
Wingens M, Jacobs-Oomen S, van der Woning SP, Stortelers C, van Zoelen EJ. Wingens M, et al. Biochemistry. 2006 Apr 11;45(14):4703-10. doi: 10.1021/bi060087m. Biochemistry. 2006. PMID: 16584205 - Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin.
Kani K, Warren CM, Kaddis CS, Loo JA, Landgraf R. Kani K, et al. J Biol Chem. 2005 Mar 4;280(9):8238-47. doi: 10.1074/jbc.M410944200. Epub 2004 Dec 20. J Biol Chem. 2005. PMID: 15611073 - Structural insights into ligand-induced activation of the insulin receptor.
Ward C, Lawrence M, Streltsov V, Garrett T, McKern N, Lou MZ, Lovrecz G, Adams T. Ward C, et al. Acta Physiol (Oxf). 2008 Jan;192(1):3-9. doi: 10.1111/j.1748-1716.2007.01781.x. Acta Physiol (Oxf). 2008. PMID: 18171424 Review. - EGFR family: structure physiology signalling and therapeutic targets.
Burgess AW. Burgess AW. Growth Factors. 2008 Oct;26(5):263-74. doi: 10.1080/08977190802312844. Growth Factors. 2008. PMID: 18800267 Review.
Cited by
- The ERBB3 receptor in cancer and cancer gene therapy.
Sithanandam G, Anderson LM. Sithanandam G, et al. Cancer Gene Ther. 2008 Jul;15(7):413-48. doi: 10.1038/cgt.2008.15. Epub 2008 Apr 11. Cancer Gene Ther. 2008. PMID: 18404164 Free PMC article. Review. - An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, Gu J, Huang A, Haubst N, Zehetmeier C, Haberl M, Elis W, Kunz C, Heidt AB, Herlihy K, Murtie J, Schuller A, Arteaga CL, Sellers WR, Ettenberg SA. Garner AP, et al. Cancer Res. 2013 Oct 1;73(19):6024-35. doi: 10.1158/0008-5472.CAN-13-1198. Epub 2013 Aug 8. Cancer Res. 2013. PMID: 23928993 Free PMC article. - Insulin and epidermal growth factor receptor family members share parallel activation mechanisms.
Ferguson KM, Hu C, Lemmon MA. Ferguson KM, et al. Protein Sci. 2020 Jun;29(6):1331-1344. doi: 10.1002/pro.3871. Epub 2020 Apr 28. Protein Sci. 2020. PMID: 32297376 Free PMC article. Review. - HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks.
Landgraf R. Landgraf R. Breast Cancer Res. 2007;9(1):202. doi: 10.1186/bcr1633. Breast Cancer Res. 2007. PMID: 17274834 Free PMC article. Review. - Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands.
Jin P, Zhang J, Beryt M, Turin L, Brdlik C, Feng Y, Bai X, Liu J, Jorgensen B, Shepard HM. Jin P, et al. Mol Med. 2009 Jan-Feb;15(1-2):11-20. doi: 10.2119/molmed.2008.00103. Epub 2008 Nov 17. Mol Med. 2009. PMID: 19048033 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous